Novo Nordisk's semaglutide shows improved mental and physical wellbeing as obesity treatment

New data suggests that Novo Nordisk's molecule semaglutide improves the mental and physical wellbeing of obesity patients according to results from the pharmaceutical company's Step program.
Photo: LISELOTTE SABROE//
Photo: LISELOTTE SABROE//
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

A weekly dose of Novo Nordisk's semaglutide as a treatment for obesity seems to result in weight loss as well as improved physical function and psychological wellbeing, according to results from the Danish pharmaceutical firm's phase IIIa known as Step 1.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading